310 related articles for article (PubMed ID: 33851319)
1. "Present and future of immunotherapy in Neuroendocrine Tumors".
Albertelli M; Dotto A; Nista F; Veresani A; Patti L; Gay S; Sciallero S; Boschetti M; Ferone D
Rev Endocr Metab Disord; 2021 Sep; 22(3):615-636. PubMed ID: 33851319
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy and potential predictive biomarkers in the treatment of neuroendocrine neoplasia.
Xu G; Wang Y; Zhang H; She X; Yang J
Future Oncol; 2021 Mar; 17(9):1069-1081. PubMed ID: 33136448
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a 2021 update.
Kole C; Charalampakis N; Vailas M; Tolia M; Sotiropoulou M; Tsakatikas S; Kouris NI; Tsoli M; Koumarianou A; Karamouzis MV; Schizas D
Cancer Immunol Immunother; 2022 Apr; 71(4):761-768. PubMed ID: 34471940
[TBL] [Abstract][Full Text] [Related]
4. Immunotherapy in Gastroenteropancreatic Neuroendocrine Neoplasia.
Popa Ilie IR; Georgescu CE
Neuroendocrinology; 2023; 113(2):262-278. PubMed ID: 34348340
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapies for well-differentiated grade 3 gastroenteropancreatic neuroendocrine tumors: A new category in the World Health Organization classification.
Xu JX; Wu DH; Ying LW; Hu HG
World J Gastroenterol; 2021 Dec; 27(47):8123-8137. PubMed ID: 35068858
[TBL] [Abstract][Full Text] [Related]
6. Progress in immunotherapy for neuroendocrine neoplasm of the digestive system.
Pan WX; Zhang XM; Hao SL; Han W
World J Gastroenterol; 2023 Jul; 29(26):4174-4185. PubMed ID: 37475845
[TBL] [Abstract][Full Text] [Related]
7. Narrative Review of Immunotherapy in Gastroentero-Pancreatic Neuroendocrine Neoplasms.
Kaur J; Vijayvergia N
Curr Oncol; 2023 Sep; 30(9):8653-8664. PubMed ID: 37754542
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in Neuroendocrine Neoplasms: Where Are We Now?
Fazio N; Abdel-Rahman O
Curr Treat Options Oncol; 2021 Feb; 22(3):19. PubMed ID: 33559013
[TBL] [Abstract][Full Text] [Related]
9. Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia.
Weber MM; Fottner C
Oncol Res Treat; 2018; 41(5):306-312. PubMed ID: 29742518
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological features and prognosis of gastroenteropancreatic neuroendocrine neoplasms in a Chinese population: a large, retrospective single-centre study.
Zhang M; Zhao P; Shi X; Zhao A; Zhang L; Zhou L
BMC Endocr Disord; 2017 Jul; 17(1):39. PubMed ID: 28705205
[TBL] [Abstract][Full Text] [Related]
11. Potential new applications of immunotherapy for neuroendocrine neoplasms: immune landscape, current status and future perspectives.
Bai R; Li W; Cui J
Cancer Biol Med; 2022 Oct; 19(12):1649-61. PubMed ID: 36245210
[TBL] [Abstract][Full Text] [Related]
12. Gastroenteropancreatic Neuroendocrine Neoplasms (GEP NENs): The Role of Checkpoint Inhibitors.
Arrivi G; Fazio N
Curr Cancer Drug Targets; 2022 Aug; 22(8):629-638. PubMed ID: 35034595
[TBL] [Abstract][Full Text] [Related]
13. New insights in diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms.
Yin F; Wu ZH; Lai JP
World J Gastroenterol; 2022 May; 28(17):1751-1767. PubMed ID: 35633912
[TBL] [Abstract][Full Text] [Related]
14. Immune checkpoint markers in gastroenteropancreatic neuroendocrine neoplasia.
Bösch F; Brüwer K; Altendorf-Hofmann A; Auernhammer CJ; Spitzweg C; Westphalen CB; Boeck S; Schubert-Fritschle G; Werner J; Heinemann V; Kirchner T; Angele M; Knösel T
Endocr Relat Cancer; 2019 Mar; 26(3):293-301. PubMed ID: 30608901
[TBL] [Abstract][Full Text] [Related]
15. Role of immunotherapy in gastro-enteropancreatic neuroendocrine neoplasms (gep-nens): Current advances and future directions.
Fang L; Arvind D; Dowlati A; Mohamed A
J Neuroendocrinol; 2021 Mar; 33(3):e12943. PubMed ID: 33724586
[TBL] [Abstract][Full Text] [Related]
16. The tumor immune microenvironment in gastroenteropancreatic neuroendocrine neoplasms.
Zhang WH; Wang WQ; Gao HL; Yu XJ; Liu L
Biochim Biophys Acta Rev Cancer; 2019 Dec; 1872(2):188311. PubMed ID: 31442475
[TBL] [Abstract][Full Text] [Related]
17. Bevacizumab-based combination therapy for advanced gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a systematic review of the literature.
Abdel-Rahman O; Fouad M
J Cancer Res Clin Oncol; 2015 Feb; 141(2):295-305. PubMed ID: 24990591
[TBL] [Abstract][Full Text] [Related]
18. What Is the Status of Immunotherapy in Neuroendocrine Neoplasms?
Garcia-Alvarez A; Cubero JH; Capdevila J
Curr Oncol Rep; 2022 Apr; 24(4):451-461. PubMed ID: 35171460
[TBL] [Abstract][Full Text] [Related]
19. Role of PD-L1 expression as a biomarker for GEP neuroendocrine neoplasm grading.
Cavalcanti E; Armentano R; Valentini AM; Chieppa M; Caruso ML
Cell Death Dis; 2017 Aug; 8(8):e3004. PubMed ID: 28837143
[TBL] [Abstract][Full Text] [Related]
20. The Clinical Significance of PD-L1/PD-1 Expression in Gastroenteropancreatic Neuroendocrine Neoplasia.
Wang C; Yu J; Fan Y; Ma K; Ning J; Hu Y; Niu W; Dong X; Wu Y; Li E; Dong D
Ann Clin Lab Sci; 2019 Sep; 49(4):448-456. PubMed ID: 31471333
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]